Changing to Avastin could save NHS £100m a year - Cameron Optometry | Cameron Optometry
Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

COVID-19 advice

18th November 2020

This page will have our latest information on the care we can provide during the COVID-19 pandemic. You can also find information on our Facebook page. LATEST UPDATE 2.00pm, Wednesday 18 November, ...

Read more

Is your vision roadworthy?

16th November 2020

Vision plays a vital role in driving, and as a driver it’s important that you ensure you have the best vision possible. To mark Road Safety Week, taking place from 16-22 November, The College of Opt...

Read more

Adapting appointments for all

06th November 2020

At Cameron Optometry, we have a huge range of patients who walk through our doors every day. From babies who have had cataract surgery and require specialist contact lenses, to people with rare, compl...

Read more

Treating dry eyes

09th October 2020

The huge increase in individuals working from home has resulted in an increase in patients getting in touch to ask for advice on dry eyes. It might be that people are spending more time on their devic...

Read more